Related Experiment Video
Updated: Dec 9, 2025

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
Targeted Small-Molecule Conjugates: The Future is Now
1Dipartimento di Chimica, Università degli Studi di Milano, via C. Golgi, 19, 20133, Milan, Italy.
Abstract:
In recent years, novel classes of small hetero-bifunctional compounds have been developed as tools for the treatment of cancer and other diseases through different approaches, from radio/chemotherapy and imaging to immunotherapy and protein degradation. Within this growing research area, progresses in ligand-screening procedures and hit-to-lead optimizations, together with advances in drug-release technologies, are paving the way to the future treatment of a broad range of pathologies with small targeted therapeutics.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Phase II Conjugation Reactions: Overview
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Microorganisms in Medicine and Therapeutics

